食管癌患者放疗前后血清可溶性白细胞介素－2受体水平测定  

THE LEVEL OF SOLUBLE INTERLEUKIN 2 RECEPTOR IN NESOPHAGEAL CARCINOMA PATIENTS BEFORE AND AFTER RADIOTHERAPY

作　　者：刘小平[1] 安怀伦[1] 姜缨[1] 张哲舫[1] 赵洪涛 

机构地区：[1]西安医科大学第一临床医学院肿瘤科

出　　处：《中华肿瘤杂志》1995年第2期97-99,共3页Chinese Journal of Oncology

摘　　要：作者用双抗体夹心酶联免疫吸附试验（ＥＬＩＳＡ法）检测了５７例食管癌患者放疗前后血清可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）水平，并与２０例正常对照组进行比较。结果显示：食管癌患者放疗前血清ｓＩＬ－２Ｒ水平显著高于正常对照（Ｐ＜０．００１），且升高水平与食管病变长度呈正相关；放疗后血清ｓＩＬ－２Ｒ水平较放疗前显著降低（Ｐ＜０．００１）。与正常对照组比较，差异无显著性意义（Ｐ＞０．０５），而放疗前后血清ＳＩＬ－２Ｒ水平降低程度在完全缓解和部分缓解病人之间，差异无显著性意义（Ｐ＞０．０５）。食管癌患者放疗前血清ｓＩＬ－２Ｒ水平升高，可能与患者表现的免疫功能低下有一定关系；而放疗后水平下降，可能是由于放射治疗降低了免疫细胞对ｓＩＬ－２Ｒ的释放所致。结果表明，食管癌患者血清ｓＩＬ－２Ｒ水平与其肿瘤的消长密切相关，血清ｓＩＬ－２Ｒ有可能作为疗效和判断预后的一个重要监测指标。Abstract The serum levels of soluble interleukin 2 receptor(sIL-2R)before and after radiotherapyin 57 esophageal carcinoma patients and 20 healthv controls were determined with an enzyme-li-nked immunosorbent assay. The objectives of this study were to determine the value of serumSIL-2R level as an index of tumor burden,and its predictive value in response to therapy andprognosis. The data showed that the serum sIL-2R level in esophageal carcinoma patients wassignificantly higher than that of healthy controls(P<0.001).The elevated serum sIL-2R levelscorrelated with the length of the esophageal cancer. The serum levels of sIL-2R weresignigicantly reduced at the end of radiotherapy(P<0.001).Moreover, the serum level afterradiotherapy was not different from that of healthy controls(P> 0.05).But,the reduced levelswere not related to the immediate response to radiotherapy.These results seem to suggest thatmonitoring serum sIL-2R levels has clinical and prognostic significance in patients withesophageal carcinoma.

关 键 词：食管肿瘤 放射疗法 白细胞介素2 受体 血液 

分 类 号：R735.105[医药卫生—肿瘤]